Elanco Launches Zenrelia™, a JAK Inhibitor for Dogs with Allergic and Atopic Dermatitis

Elanco has received FDA approval for Zenrelia™, a once-daily oral JAK inhibitor for treating pruritus and atopic dermatitis in dogs. Zenrelia offers superior results compared to Apoquel®, with 77% of dogs achieving clinical remission of itch. This groundbreaking solution will ship soon in the U.S., revolutionizing care for millions of itchy dogs. Learn more about Zenrelia’s benefits and how it’s changing the game in canine dermatology.